The StradomerTM Platform  GL-2045 is Gliknik's lead recombinant
stradomerTM for autoimmune diseases. It has demonstrated potent
efficacy in numerous animal models and is in IND-enabling
manufacturing. StradomersTM are recombinant compounds designed
to improve on pooled human intravenous immunoglobulin in a wide
range of diseases including Myasthenia gravis and other
neurological autoimmune disorders. They will also compete with
antibody therapies used in immune disorders such as rheumatoid
arthritis.  Publication: Fully recombinant IgG2a Fc multimers
(stradomers) effectively treat collagen-induced arthritis and
prevent idiopathic thrombocytopenic purpura in mice, Arthritis
Research & Therapy